OBJECTIVES: To evaluate the evolution of HIV-1 coreceptor tropism in proviral DNA of patients during maraviroc-based therapy. METHODS: Fourteen heavily high active antiretroviral therapy (HAART)-treated patients with a CCR5 Trofile profile were monitored over a 24 month period from the start of maraviroc therapy. Whole-blood samples were obtained at different timepoints, and coreceptor tropism was determined for proviral DNA from the V3-loop region sequence using the Geno2Pheno algorithm [false positive rate (FPR): 20%]. RESULTS: At the start of maraviroc treatment, 13/14 patients were viraemic (median: 4.33 log copies/mL). Concordance in R5 tropism (R5/R5) was observed between circulating HIV-RNA (Trofile) and HIV-DNA provirus in 10/14 patients (median FPR = 54.0%), while 4 patients showed a CXCR4-tropic R5/X4 variant in their provirus (FPR: 5.8%, 5.7%, 16.6% and 1.1%, respectively). All R5/R5 patients showed a stable HIV-1 DNA coreceptor usage. Two out of four R5/X4 patients showed a tropism shift in their archived provirus and, after 6 months a prevalence of R5-tropic virus was detected in DNA. The other two R5/X4 patients harboured the 11/25 genotype, and maintained X4 tropism in provirus during the study. Virological response did not reveal differences in RNA decay and CD4+ cell recovery in patients with discordant tropism. CONCLUSIONS: A relatively good correlation between RNA and DNA tropism was observed at baseline. Proviral DNA tropism remained stable over 24 months of maraviroc-based therapy, indicating that determination of proviral DNA V3 sequence could be used in tropism prediction in clinical practice. The data also confirm the importance of the 11/25 rule in predicting viral tropism.
OBJECTIVES: To evaluate the evolution of HIV-1 coreceptor tropism in proviral DNA of patients during maraviroc-based therapy. METHODS: Fourteen heavily high active antiretroviral therapy (HAART)-treated patients with a CCR5 Trofile profile were monitored over a 24 month period from the start of maraviroc therapy. Whole-blood samples were obtained at different timepoints, and coreceptor tropism was determined for proviral DNA from the V3-loop region sequence using the Geno2Pheno algorithm [false positive rate (FPR): 20%]. RESULTS: At the start of maraviroc treatment, 13/14 patients were viraemic (median: 4.33 log copies/mL). Concordance in R5 tropism (R5/R5) was observed between circulating HIV-RNA (Trofile) and HIV-DNA provirus in 10/14 patients (median FPR = 54.0%), while 4 patients showed a CXCR4-tropic R5/X4 variant in their provirus (FPR: 5.8%, 5.7%, 16.6% and 1.1%, respectively). All R5/R5 patients showed a stable HIV-1 DNA coreceptor usage. Two out of four R5/X4 patients showed a tropism shift in their archived provirus and, after 6 months a prevalence of R5-tropic virus was detected in DNA. The other two R5/X4 patients harboured the 11/25 genotype, and maintained X4 tropism in provirus during the study. Virological response did not reveal differences in RNA decay and CD4+ cell recovery in patients with discordant tropism. CONCLUSIONS: A relatively good correlation between RNA and DNA tropism was observed at baseline. Proviral DNA tropism remained stable over 24 months of maraviroc-based therapy, indicating that determination of proviral DNA V3 sequence could be used in tropism prediction in clinical practice. The data also confirm the importance of the 11/25 rule in predicting viral tropism.
Authors: Clara Lehmann; Martin Däumer; Ibrahim Boussaad; Tobias Sing; Niko Beerenwinkel; Thomas Lengauer; Norbert Schmeisser; Christoph Wyen; Gerd Fätkenheuer; Rolf Kaiser Journal: J Clin Virol Date: 2006-09-26 Impact factor: 3.168
Authors: Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst Journal: J Virol Date: 2006-05 Impact factor: 5.103
Authors: Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: S Philpott; B Weiser; K Anastos; C M Kitchen; E Robison; W A Meyer; H S Sacks; U Mathur-Wagh; C Brunner; H Burger Journal: J Clin Invest Date: 2001-02 Impact factor: 14.808
Authors: Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins Journal: J Virol Date: 2003-12 Impact factor: 5.103
Authors: S Baroncelli; C M Galluzzo; M Andreotti; M F Pirillo; V Fragola; L E Weimer; M Giuliano; S Vella; L Palmisano Journal: Eur J Clin Microbiol Infect Dis Date: 2013-07-04 Impact factor: 3.267
Authors: Saleta Sierra; J Nikolai Dybowski; Alejandro Pironti; Dominik Heider; Lisa Güney; Alex Thielen; Stefan Reuter; Stefan Esser; Gerd Fätkenheuer; Thomas Lengauer; Daniel Hoffmann; Herbert Pfister; Björn Jensen; Rolf Kaiser Journal: PLoS One Date: 2015-05-13 Impact factor: 3.240
Authors: Guinevere Q Lee; Winnie Dong; Theresa Mo; David J H F Knapp; Chanson J Brumme; Conan K Woods; Steve Kanters; Benita Yip; P Richard Harrigan Journal: PLoS One Date: 2014-06-06 Impact factor: 3.240
Authors: Pablo Ferrer; Luisa Montecinos; Mario Tello; Rocio Tordecilla; Consuelo Rodríguez; Marcela Ferrés; Carlos M Pérez; Carlos Beltrán; Maria A Guzmán; Alejandro Afani Journal: Virol J Date: 2013-10-28 Impact factor: 4.099